Hemmo Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 26-06-2024
- Paid Up Capital ₹ 2.91 M
as on 26-06-2024
- Company Age 45 Year, 6 Days
- Last Filing with ROC 31 Mar 2021
- Open Charges ₹ 250.00 M
as on 26-06-2024
- Satisfied Charges ₹ 10.63 M
as on 26-06-2024
- Revenue 44.62%
(FY 2021)
- Profit 68.07%
(FY 2021)
- Ebitda 115.54%
(FY 2021)
- Net Worth 39.37%
(FY 2021)
- Total Assets 38.40%
(FY 2021)
About Hemmo Pharmaceuticals
- CIN/LLPIN
U17100MH1979PTC021857
- Company No.
021857
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Nov 1979
- Date of AGM
30 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Hemmo Pharmaceuticals Private Limited offer?
Hemmo Pharmaceuticals Private Limited offers a wide range of products and services, including Common Disease Medicines, Steroid.
Who are the key members and board of directors at Hemmo Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Amit Bapat  | Director | 26-Nov-2021 | Current |
| Surinder Gulati | Director | 22-Jun-2021 | Current |
| Madhu Utamsingh | Director | 01-Aug-2008 | Current |
Financial Performance and Corporate Structure Insights of Hemmo Pharmaceuticals.
Hemmo Pharmaceuticals Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 44.62% increase. The company also saw a substantial improvement in profitability, with a 68.07% increase in profit. The company's net worth Soared by an impressive increase of 39.37%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Hemmo Pharmaceuticals?
In 2021, Hemmo Pharmaceuticals had a promoter holding of 100.01%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Piramal Pharma Ii Private Limited
Active 2 years 5 monthsAmit Bapat and Surinder Gulati are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 23 Mar 2022 | ₹25.00 Cr | Open |
Indian Overseas Bank Creation Date: 22 Sep 1998 | ₹0.32 M | Satisfied |
Oriental Bank Of Commerce Creation Date: 18 Sep 1995 | ₹5.00 M | Satisfied |
How Many Employees Work at Hemmo Pharmaceuticals?
Hemmo Pharmaceuticals has a workforce of 325 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hemmo Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hemmo Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
